AVILEX PHARMA ApS: Financial statements 2015
CVR: 34896828
Source: annual report 2015, Danish Business Authority
01/01/2015 – 31/12/2015
AVILEX PHARMA ApS (CVR 34896828) has filed annual accounts for 2015. In 2015, the company reported a net result of DKK -7,570,524 compared with DKK -1,224,080 the year before. Equity in the 2015 report amounted to DKK -279,218. The company had 3 employees in the financial year.
- Profit/Loss
- DKK -7,570,524
- Equity
- DKK -279,218
- Total Assets
- DKK 10,411,579
- Employees
- 3
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2015 | - | - | -7.6 mio. | -279 t. | 3 |
| 2014 | - | - | -1.2 mio. | -4.1 mio. | 0 |
| 2013 | - | - | -2.9 mio. | -2.9 mio. | - |
Official annual report
How creditworthy is AVILEX PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2015
As of September 1, 2015, Emmanuelle Coutanceau has joined the board of directors of AVILEX PHARMA ApS.
As of August 14, 2015, Bobby G Soni has left the board of directors of AVILEX PHARMA ApS.
AVILEX PHARMA ApS has published its annual report for 2014. The net result was DKK -1,224,080.
As of March 2, 2015, Grant Thornton, Godkendt Revisionspartnerselskab has been appointed auditor of AVILEX PHARMA ApS.
As of March 2, 2015, EY Godkendt Revisionspartnerselskab has stepped down as auditor of AVILEX PHARMA ApS.
About AVILEX PHARMA ApS
AVILEX PHARMA ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristian Strømgaard. The board consists of Raymond George Hill (chair), Camilla Petrycer Hansen, Jonathan Mark Treherne and Kristian Strømgaard. The company's owners include Novo Holdings A/S, MIKAEL SØNDERGÅRD THOMSEN ApS and KRISTIAN STRØMGAARD HOLDING ApS. The company has 3 employees (2018). In 2025, the company reported a net result of DKK -4,530,000 compared with DKK -4,428,000 the year before. Equity in the 2025 report amounted to DKK -10,797,000.